LATEST NEWS: Pfizer halts study of lymphoma drug unlikely to help survival - (Reuters) - Pfizer Inc, which has been on a hot streak with three recent approvals of cancer drugs, stumbled on Monday, saying it was halting a late-stage trial of a drug for aggressive non-Hodgkin lymphoma after independent monitors found it was not likely to improve survival.
LATEST NEWS: Swine virus confirmed in Iowa, Indiana hog herds - (Reuters) - Farms in two of the nation's leading pork producing states have tested positive for the potentially fatal porcine epidemic diarrhea virus (PEDV), U.S. pork industry veterinarian official said Monday.
LATEST NEWS: Does prostate cancer treatment help older, sick men? - NEW YORK (Reuters Health) - Older men with other illnesses may not live long enough to benefit from aggressive prostate cancer treatments, such as prostate removal or radiation, and they'd have to live with their side effects, says a new study.
LATEST NEWS: Pricey radiation no better post prostatectomy: study - NEW YORK (Reuters Health) - Men who get an older and less costly form of radiation after their cancerous prostates are removed fare just as well as men who get a new and expensive type of radiation, according to a new study.
LATEST NEWS: Health sites too complex, full of cliches: study - NEW YORK (Reuters Health) - The importance of health literacy hit home for Lisa Gualtieri when a Cambodian refugee diagnosed with cancer asked her to act as a patient advocate.
LATEST NEWS: Royalty raises Elan bid, issues ultimatum to shareholders - DUBLIN/NEW YORK (Reuters) - Royalty Pharma raised its hostile bid for Elan to $12.50 per share and threatened to withdraw the bid if Elan shareholders approve a series of defensive transactions announced by the Irish drug firm.
LATEST NEWS: Bayer says lung drug shows promise in prolonged trial - FRANKFURT (Reuters) - Bayer said extended use of its experimental riociguat pill to treat a life-threatening form of high blood pressure in the lungs was shown to be safe and effective in a prolonged trial.
LATEST NEWS: Actavis to buy Warner Chilcott in $5 billion stock deal - (Reuters) - Generic drugmaker Actavis Inc, itself a recent takeover target, said on Monday it would buy specialty pharmaceutical company Warner Chilcott Plc for $5 billion in stock to expand its branded drug portfolio, lower taxes and increase profits.
LATEST NEWS: XenoPort to drop multiple sclerosis drug, shares fall - (Reuters) - XenoPort Inc said it would stop development of an experimental multiple sclerosis treatment it planned to launch in 2015 after a late-stage trial failed to show significant improvement over a placebo.